Oncodesign® Presents its Latest Scientific Advances at the AACR Annual Conference
News Apr 19, 2010
Oncodesign, a specialist in the identification of novel cancer therapies, announces that it will present eight scientific posters at the annual conference of the American Association for Cancer Research in Washington DC, April 17-20.
As in previous years, Oncodesign is showcasing its latest technological advances at the AACR. The company’s translational research platform is focused on two main technology areas: the development of new experimental models and new pharmaco-imaging tools. In the field of preclinical models, Oncodesign is presenting its new platform for the production of “chi-Mice”, humanized chimeric animals.
“These models combine our research into grafting tumors directly from patients and the reconstitution of a human hematological and immune system in a severely immunodeficient mouse,” said Philippe Genne, CEO of Oncodesign. “Our mouse humanization platform means our customers can have these models in house or let us carry out their preclinical evaluation in our labs.” The procedures and characterization of the humanized models are presented in the two posters produced in conjunction with Oncodesign’s scientific partners (#394, #4169).
Oncodesign’s core business is the evaluation of new therapies in oncology. This is represented by four posters produced in conjunction with the company’s customers (#571, #1367, #5459, #5490). Oncodesign’s world-class in vitro and in vivo pharmacology platform has made significant contributions to the biodistribution and the efficacy of Oncodesign’s customers’ products. In the context of this translational research, Oncodesign’s scientific team will present its results with biomarkers of antitumoral efficacy using MRI and with serum biomarkers for the development of bone metastases in tumors of the prostate in the Nude rat.
The last innovation presented is the process of translational drug discovery which combines the Nanocyclix® medicinal chemistry technology and the in vivo pharmacological approach (#740). “Our goal is to offer our customers access to highly specific kinases and to discover new therapeutic molecules or imaging biomarkers using biological assays very close to clinical reality.”
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018